Natera, Inc., a leading genetic testing company headquartered in the United States, has been at the forefront of the genomics industry since its founding in 2004. With a strong presence in North America and expanding operations globally, Natera focuses on reproductive health, oncology, and organ transplantation. The company is renowned for its innovative non-invasive prenatal testing (NIPT) and advanced cancer diagnostics, which leverage cutting-edge technology to provide accurate and actionable insights. Natera's unique approach to genetic testing has positioned it as a trusted partner in healthcare, with significant milestones including the launch of its flagship product, Panorama, which revolutionised prenatal screening. With a commitment to improving patient outcomes, Natera continues to achieve notable recognition in the market, solidifying its status as a pioneer in the field of genetic testing.
How does Natera's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Natera's score of 51 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Natera reported total carbon emissions of approximately 154,029,510 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 146,322,600 kg CO2e. The breakdown of emissions includes Scope 1 emissions of approximately 4,597,760 kg CO2e and Scope 2 emissions of about 3,109,150 kg CO2e. Natera has set ambitious climate commitments, aiming to reduce absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2023 as the base year. Additionally, the company targets a 51.6% reduction in Scope 3 emissions from upstream transportation and distribution per test processed within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global goal of limiting temperature rise to 1.5°C. The company is also committed to ensuring that approximately 70.91% of its suppliers, covering emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2030. This comprehensive approach underscores Natera's dedication to addressing its carbon footprint and contributing to climate action within the healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 6,004,700 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,660,810 | 0,000,000 | 0,000,000 |
| Scope 3 | 87,380,350 | 000,000,000 | 000,000,000 |
Natera's Scope 3 emissions, which increased by 12% last year and increased by approximately 67% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 84% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Natera has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Natera's sustainability data and climate commitments